Neurocrine Biosciences Reports Positive INGREZZA Data and Strong Q2 Results
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) released KINECT-PRO data showing that its drug INGREZZA significantly reduces the daily burden of tardive dyskinesia in patients. The Phase 4 study found that about 58% of participants achieved symptomatic remission on clinician-rated movement severity, with benefits observed across all levels of initial symptom severity and within weeks. The positive data follows a strong Q2 performance for Neurocrine, where total revenue rose by 39% year-over-year to $959 million. INGREZZA sales increased by 15% to $716 million, prompting the company to raise its full-year guidance for the drug’s sales between $2.825 billion and $2.875 billion. The growth was supported by contributions from newer drugs CRENESSITY ($184 million) and VYKAT XR ($54 million), acquired in May 2026. However, this expansion came at a cost: Neurocrine’s cash reserves dropped sharply due to the $2.9 billion acquisition of Soleno Therapeutics. The company now has a new $1.0 billion credit facility and faces rising R&D and SG&A expenses as it advances its pipeline toward 2027 readouts.
Topics: drug efficacy INGREZZA KINECT-PRO study Neurocrine Biosciences tardive dyskinesia